The role of active surveillance and cytoreductive nephrectomy in metastatic renal cell carcinoma.

Treatment of metastatic renal cell carcinoma (mRCC) has been revolutionized by an expanding armamentarium of systemic therapies, which have resulted in improved patient outcomes. Multimodal approaches that include cytoreductive nephrectomy (CN), immunotherapy, and targeted therapy are necessary to optimize clinical care. Active surveillance (AS) and CN are two cornerstones of treatment in mRCC, which require reexamination in the context of new systemic therapies. Herein, we review the data and provide a practical approach for the incorporation of AS and CN in the management of mRCC.

Cancer treatment and research communications. 2020 Feb 22 [Epub ahead of print]

Amanda Nizam, Jonah A Schindelheim, Moshe C Ornstein

Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, United States., Department of Medicine, Touro College of Osteopathic Medicine, Middletown, NY, United States., Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, United States. Electronic address: .

email news signup